TY  - JOUR
A1  - Kress, Michaela
A1  - Hüttenhofer, Alexander
A1  - Landry, Marc
A1  - Kuner, Rohini
A1  - Favereaux, Alexandre
A1  - Greenberg, David
A1  - Bednarik, Josef
A1  - Heppenstall, Paul
A1  - Kronenberg, Florian
A1  - Malcangio, Marzia
A1  - Rittner, Heike
A1  - Üçeyler, Nurcan
A1  - Trajanoski, Zlatko
A1  - Mouritzen, Peter
A1  - Birklein, Frank
A1  - Sommer, Claudia
A1  - Soreq, Hermona
T1  - microRNAs in nociceptive circuits as predictors of future clinical applications
JF  - Frontiers in Molecular Neuroscience
N2  - Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain, and non-coding RNAs – and microRNAs (miRNAs) in particular – regulate both immune and neuronal processes. Specifically, miRNAs control macromolecular complexes in neurons, glia and immune cells and regulate signals used for neuro-immune communication in the pain pathway. Therefore, miRNAs may be hypothesized as critically important master switches modulating chronic pain. In particular, understanding the concerted function of miRNA in the regulation of nociception and endogenous analgesia and defining the importance of miRNAs in the circuitries and cognitive, emotional and behavioral components involved in pain is expected to shed new light on the enigmatic pathophysiology of neuropathic pain, migraine and complex regional pain syndrome. Specific miRNAs may evolve as new druggable molecular targets for pain prevention and relief. Furthermore, predisposing miRNA expression patterns and inter-individual variations and polymorphisms in miRNAs and/or their binding sites may serve as biomarkers for pain and help to predict individual risks for certain types of pain and responsiveness to analgesic drugs. miRNA-based diagnostics are expected to develop into hands-on tools that allow better patient stratification, improved mechanism-based treatment, and targeted prevention strategies for high risk individuals.
KW  - chronic pain
KW  - biomarker
KW  - polymorphism
KW  - miRNA-based diagnostics
KW  - miRNA expression patterns
KW  - miRNA polymorphisms
KW  - antagomir
KW  - miRNA-based analgesic
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-154597
VL  - 6
IS  - 33
ER  - 
TY  - JOUR
A1  - Erbacher, Christoph
A1  - Vaknine, Shani
A1  - Moshitzky, Gilli
A1  - Lobentanzer, Sebastian
A1  - Eisenberg, Lina
A1  - Evdokimov, Dimitar
A1  - Sommer, Claudia
A1  - Greenberg, David S.
A1  - Soreq, Hermona
A1  - Üçeyler, Nurcan
T1  - Distinct CholinomiR blood cell signature as a potential modulator of the cholinergic system in women with fibromyalgia syndrome
JF  - Cells
N2  - Fibromyalgia syndrome (FMS) is a heterogeneous chronic pain syndrome characterized by musculoskeletal pain and other key co-morbidities including fatigue and a depressed mood. FMS involves altered functioning of the central and peripheral nervous system (CNS, PNS) and immune system, but the specific molecular pathophysiology remains unclear. Anti-cholinergic treatment is effective in FMS patient subgroups, and cholinergic signaling is a strong modulator of CNS and PNS immune processes. Therefore, we used whole blood small RNA-sequencing of female FMS patients and healthy controls to profile microRNA regulators of cholinergic transcripts (CholinomiRs). We compared microRNA profiles with those from Parkinson's disease (PD) patients with pain as disease controls. We validated the sequencing results with quantitative real-time PCR (qRT-PCR) and identified cholinergic targets. Further, we measured serum cholinesterase activity in FMS patients and healthy controls. Small RNA-sequencing revealed FMS-specific changes in 19 CholinomiRs compared to healthy controls and PD patients. qRT-PCR validated miR-182-5p upregulation, distinguishing FMS patients from healthy controls. mRNA targets of CholinomiRs bone morphogenic protein receptor 2 and interleukin 6 signal transducer were downregulated. Serum acetylcholinesterase levels and cholinesterase activity in FMS patients were unchanged. Our findings identified an FMS-specific CholinomiR signature in whole blood, modulating immune-related gene expression.
KW  - fibromyalgia syndrome
KW  - cholinergic system
KW  - CholinomiRs
KW  - microRNA
KW  - miR-182-5p
KW  - Parkinson's disease
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270686
SN  - 2073-4409
VL  - 11
IS  - 8
ER  -